Status:

UNKNOWN

Real-time Early Detection of Nephrotoxicity by Urinary Biomarker Analysis With SeroFlow Technology

Lead Sponsor:

National University Hospital, Singapore

Collaborating Sponsors:

Agency for Science, Technology and Research

Conditions:

Acute Kidney Injury

Eligibility:

All Genders

18-100 years

Phase:

NA

Brief Summary

The study aims to perform real-time validation of the RenaFAST kit (a point-of-care test kit that quantifies three urinary proteins) in predicting acute kidney injury(AKI) among patients prescribed dr...

Detailed Description

All eligible patients who fulfill the inclusion and exclusion criteria will be approached for consent. The patients with the highest AKI risk (with all 3 urine biomarkers, Clusterin, monocyte chemoatt...

Eligibility Criteria

Inclusion

  • Patients who receive a projected ≥7 days of therapy of antimicrobials including aminoglycosides (i.e., gentamicin or amikacin), vancomycin, polymyxin, amphotericin and foscarnet.
  • Patients who receive a projected ≥7 days of Calcineurin inhibitors (cyclosporin, tacrolimus)
  • Patients who receive a projected ≥7 days of anti-virals (Cidofovir and Ganciclovir)
  • Patients who receive Anti-cancer drugs (Chemotherapy such as cisplatin, Ifosfamide, Methotrexate, Pemetrexed) or
  • Patients who receive Anti-cancer drugs (Immunotherapy such as immune checkpoint inhibitors as well as types of VGEF inhibitors that are associated with acute kidney injury)

Exclusion

  • Patients with AKI prior to therapy initiation.
  • Patients with baseline eGFR \< 15 mL/min/1.73m2 (stage 5 chronic kidney disease)
  • Patients admitted to intensive care unit at study baseline, as critical illness is a natural confounder to AKI
  • Females who are pregnant
  • Immediate post-kidney transplant recipients (initial 3 months following transplant).

Key Trial Info

Start Date :

November 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2024

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06124885

Start Date

November 1 2023

End Date

December 1 2024

Last Update

November 9 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National University Hospital

Singapore, Singapore